Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?
The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.
No hay comentarios:
Publicar un comentario